{'fraction_non_alphanumeric': 0.03101424979044426, 'fraction_numerical': 0.016764459346186086, 'mean_word_length': 5.03030303030303, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Role of bcl-2 in endometrioid corpus cancer: an experimental study.

BACKGROUND
Bcl-2 expression appears to be under hormonal control in normal endometrium and to correlate with hormone receptor status in endometrial cancer. The aim of this study was to assess bcl-2 expression in endometrial cancer.


MATERIALS AND METHODS
Hysterectomy specimens from 125 patients with endometrial cancer were stained for bcl-2. Estrogen receptor (ER) and progesterone receptor (PR) levels were quantified with a dextran-coated charcoal assay.


RESULTS
Bcl-2 expression correlated significantly with endometrioid histology and high levels of ER and PR (p < 0.05). For the entire population, bcl-2 expression was not significantly associated with the presence of extrauterine disease. However, when only patients with grade 1 or 2 endometrioid histology were considered, tumors with bcl-2 expression were significantly (p < 0.05) more likely to present with extrauterine disease than those not expressing bcl-2.


CONCLUSION
Bcl-2-mediated inhibition of apoptosis may be important in the acquisition of molecular alterations and development of metastases in a subset of hormone-dependent endometrial cancers.